COMPANY OVERVIEW

ABOUT US
SCROLL

OVERVIEW

Cell Reprogramming
Popularization-Leading Company

Game Changer’s technology opens up a new future.

STEMON

CORE VALUE

Honest Management
Honest Management

We walk the right path by complying
with basics and principles through
transparent management.

Innovative Challenges and Research
Innovative Challenges and Research

We present technological innovation and a new
paradigm through the development of original
technology for cell therapy.

With the World
With the World

We pursue values that contribute to both us and society.

MISSION

New Health

Good Health

MORE
MISSION

New Health

Good Health

STEMON Inc. will do its best to ensure that mankind is in a state of complete physical,
mental and social well-being through the development of various intractable disease treatments.
MISSON & VISION

New Future

Digital Cell Therapy

MORE
MISSON & VISION

New Future

Digital Cell Therapy

STEMON Inc. lead the popularization of autologous cell therapy with the Entr technology-based automation system, thereby realizing the era of digital cell therapy where disease prevention and management can be done by ourselves.
PHILOSOPHY

A Beautiful Promise to Create a
Healthy Tomorrow!

Creating new values with technology that goes beyond limits, it is the most important thing for us.
A Beautiful Promise to Create a Healthy Tomorrow!
That is the product of today's constant challenge and research.

STEMON

HISTORY

  • March, 2018

    Company established
    (Gangnam-daero, Gangnam-gu, Seoul)

  • May, 2018

    Selected as First Penguin Project by Korea Credit Guarantee Fund

    Device and Method for Inducing Pluripotent Cells Using Energy and 9 Cases
    (Technology transfer and patent transfer from Catholic Kwandong University)

  • 2018

    With regard to technology development of Entr and original technology of Reprosome, SCI-grade papers published, 7 patents applied and 2 registered

  • August, 2018

    Company-affiliated institute registered

    Head office relocated (Pangyo Techno Valley)

  • September, 2018

    Company-affiliated institute established

    Selected in TIPS Program

  • October, 2018

    Venture Business certificated

  • December, 2018

    Seed investment attracted (Daekyo Investment, POSCO Asset Management, Actner Lab)

  • 2019

    With regard to Entr technology, SCI-grade papers published, 1 patent applied and 12 registered

  • October, 2019

    Reprosome ICID raw material listed

  • 2020

    With regard to Entr technology, 2 patent applied and 2 registered

  • June, 2020

    Selected as a company eligible for SME venture innovative growth support in the BIG3 field (Bio-Health)

  • September, 2020

    Office building relocated (Galmachi-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do) 2020.10 October, 2020

  • October, 2020

    Factory approved (Galmachi-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do)

  • 2021

    With regard to application of Entr technology, 12 patent applied and 3 registered/p>

  • February, 2021

    Overseas supply of products concluded through business-to-business(B2B) cooperation (THETISBIO Co., Ltd., EYESEL Co.,Ltd.)

  • June, 2021

    Series A investment attracted (Woori Bank, Korea SMEs and Startups Agency, Alico Pharmaceutical)

  • July, 2021

    Signed MOU with Alico Pharmaceutical for feminine hygiene products

  • August, 2021

    ISO 22716, ISO 9001 certified

  • October, 2021

    IRB approved from the Ministry of Health and Welfare (research for treatment of inflammatory immune diseases)